Dr. Tougeron David
My Social Links

Dr. Tougeron David

Research Scientist
Poitiers University Hospital, France


Highest Degree
Ph.D. in Immune Response in Colorectal Cancer from Poitiers University Hospital, France

Share this Profile

Biography

Dr. Tougeron David has obtained his Ph.D. in Immune Response in Colorectal Cancer from Poitiers University Hospital, France. Currently he is working at Poitiers University Hospital, France. His main area of interest focuses on Biomedical Sciences, and Molecular Sciences. His area of expertise includes Colorectal Cancer, Cancer Immunity, Digestive Cancer, Gastric Cancer, Autophagy, Oesophageal Cancer, Pancreatic Cancer, Electroporation, Liver Cancer, Chemotherapy, Rectal Cancer, Chemoradiation, Kras, Braf, Chemosensitivity, Radiosensitivity, Microsatellite Instability, and Adjuvant Chemotherapy. He has 31 publications in journals as author/co-author.

Area of Interest:

Biomedical Sciences
100%
Colorectal Cancer
62%
Pancreatic Cancer
90%
Cancer Immunity
75%
Electroporation
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
244
Abstracts
4

Selected Publications

  1. Tougeron, D., T. Lecomte, J.C. Pages, C. Collin and C. Villalva et al., 2013. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol., 24: 1267-1273.
    PubMed  |  
  2. Tougeron, D., P. Maby, N. Elie, E. Fauquembergue and F. Le Pessot et al., 2013. Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers. Plos One, Vol. 18, .
    PubMed  |  Direct Link  |  
  3. Sarafan-Vasseur, N., D. Sefrioui, D. Tougeron, A. Lamy and F. Blanchard et al., 2013. Genetic variations of the A13/A14 repeat located within the EGFR 3[prime] untranslated region have no oncogenic effect in patients with colorectal cancer. BMC Cancer, Vol. 13, .
    Direct Link  |  
  4. Tougeron, D., M. Scotte, H. Hamidou, A. Benyoucef and F. Di Fiore et al., 2012. Definitive Chemoradiotherapy in patients with esophageal adenocarcinoma: An alternative to surgery? J. Surg. Oncol., 105: 761-766.
    PubMed  |  
  5. Tougeron, D., G. Fotsing, V. Barbu and M. Beauchant, 2012. ABCB4/MDR3 gene mutations and Cholangiocarcinomas. J. Hepatol., 57: 467-468.
    PubMed  |  
  6. Tougeron, D., B. Roullet, B. Paillot, F. Fruge and H. Hamidou et al., 2012. Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: A bicentric analysis. Dig. Liver Dis., 44: 350-354.
    PubMed  |  
  7. Thevenot, T., T. Degand, N. Grelat, L. Elkrief and C. Christol et al., 2012. A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. Liver Int., 33: 389-397.
    PubMed  |  
  8. Zaanan, A., M. Gauthier, D. Malka, C. Locher and J.M. Gornet et al., 2011. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: A multicenter AGEO study. Cancer, 117: 1422-1428.
    PubMed  |  
  9. Tougeron, D., J.P. Richer and C. Silvain, 2011. Treatment of esophageal adenocarcinoma. J. Visc. Surg., 48: 161-170.
  10. Tougeron, D., A. Ferru, J.P. Faure and C. Silvain, 2011. Treatment of rectal cancer with synchronous hepatic metastases. Hepato-gastro, 18: 146-154.
  11. Chung, K.Y.C., C. Tomowiak, M. Yacoub, T. Barrioz, C. Silvain and D. Tougeron, 2011. A rare case of mantle cell lymphoma as lymphomatous polyposis with widespread involvement of the digestive tract. Clin. Res. Hepatol. Gastroenterol., 35: 74-78.
    CrossRef  |  PubMed  |  
  12. Zaanan, A., L. Costes, M. Gauthier, D. Malka and C. Locher et al., 2010. Chemotherapy of advanced small-bowel adenocarcinoma: A multicenter AGEO study. Ann. Oncol., 21: 1786-1793.
    Direct Link  |  
  13. Tougeron, D., H. Hamidou, M. Scotte, F. Di Fiore, M. Antonietti, B. Paillot and P. Michel, 2010. Esophageal cancer in the elderly: An analysis of the factors associated with treatment decisions and outcomes. BMC Cancer, Vol. 10, .
    Direct Link  |  
  14. Tougeron, D., E. Wierzbicka-Hainaut, S. Osdoit, C. Chagneau-Derrode, M. Yacoub and C. Silvain, 2010. Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment. Eur. J. Dermatol., 20: 854-856.
    PubMed  |  
  15. Tougeron, D., B. Paillot and P. Michel, 2010. Outcome of primary tumor in patients with synchronous stage IV colon or rectal cancer: So much the same yet so different. Gastroenterol. Clin. Biol., 34: e15-e16.
    CrossRef  |  Direct Link  |  
  16. Fauquembergue, E., O. Toutirais, D. Tougeron, A. Drouet and M.L. Gallo et al., 2010. Human carcinoembryonic antigen is not a suitable target for T cell-based immunotherapy. Rev. Prat., 60: 129-137.
  17. Fauquembergue, E., O. Toutirais, D. Tougeron, A. Drouet and M. Le Gallo et al., 2010. HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy. J. Immunother., 33: 402-413.
    Direct Link  |  
  18. Tougeron, D., H. Hamidou, F. Dujardin, C. Maillard, F.D. Fiore and P. Michel, 2009. Unusual skeletal muscle metastasis from gastric carcinoma. Gastroenterol. Clin. Biol., 33: 485-487.
    PubMed  |  
  19. Tougeron, D., G. Savoye, C. Savoye-Collet, E. Koning, F. Michot and E. Lerebours, 2009. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig. Dis. Sci., 54: 1746-1752.
    PubMed  |  
  20. Tougeron, D., F.D. Fiore, B. Lefebure, H. Hamidou and J.J. Tuech et al., 2009. Control of pelvic local symptoms in patients with rectal cancer and synchronous metastases. Gastroenterol. Clin. Biol., 33: 1106-1113.
    CrossRef  |  Direct Link  |  
  21. Tougeron, D., E. Fauquembergue, A. Rouquette, F.L. Pessot and R. Sesboue et al., 2009. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod. Pathol., 22: 1186-1195.
    CrossRef  |  Direct Link  |  
  22. Tougeron, D., B. Tougeron-Brousseau, Z. Nasser, M. Benzerroug and B. Lefebure et al., 2009. Unusual iris metastasis from anal cancer: A case report. Dig. Liver Dis., Vol. 41 .
    PubMed  |  
  23. Oden-Gangloff, A., F.D. Fiore, F. Bibeau, A. Lamy and G. Bougeard et al., 2009. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br. J. Cancer, 100: 1330-1335.
    PubMed  |  
  24. Tougeron, D., F.D. Fiore, S. Thureau, N. Berbera and I. Iwanicki-Caron et al., 2008. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br. J. Cancer, 99: 1586-1592.
    PubMed  |  
  25. Tougeron, D., B. Lefebure, G. Savoye, J.J. Tuech, F.D. Fiore and P. Michel, 2008. Small-bowel adenocarcinoma in patient with crohn's disease: Report of a series of three cases. Scand. J. Gastroenterol., 43: 1397-1400.
    CrossRef  |  PubMed  |  
  26. Iwanicki-Caron. I., F.D. Fiore, I. Roque, E. Astruc and M. Stetiu et al., 2008. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J. Clin. Oncol., 26: 3681-3686.
    CrossRef  |  Direct Link  |  
  27. Tougeron, D., F.D. Fiore, H. Hamidou, O. Rigal and M. Scotte et al., 2007. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: A matched-pair analysis. Oncology, 73: 328-334.
    PubMed  |  
  28. Tougeron, D., J. Mauillon and J.L. Tranvouez, 2006. Severe varicella infection during treatment with infliximab for Crohn's disease. Gastroenterol Clin. Biol., 30: 1410-1413.
    PubMed  |